Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR² Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering healthcare companies London, UK – 23 April 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Dr. Garry Menzel as Operating Partner. Garry brings a unique blend of scientific, ...

Core Viewpoint - Adaptimmune Therapeutics plc's strategic collaboration with Roche's Genentech has been terminated, leading to a 10% drop in ADAP shares, indicating investor disappointment and a setback for the company [1][2]. Company Developments - The collaboration, initiated in 2021, aimed to develop allogeneic cell therapies for multiple oncology indications, including two components: allogeneic T-cell therapies for shared cancer targets and personalized allogeneic T-cell therapies [1]. - Adaptimmune received an upfront payment of $150 million and was entitled to additional payments of $150 million over five years, along with milestone payments exceeding $3 billion in total value [1]. - Despite the setback, management remains optimistic about the long-term potential of its iPSC-based allogeneic platform and is focused on launching afami-cel, its first product in the sarcoma franchise, pending FDA approval [2]. Product Pipeline - Afami-cel is intended for the treatment of advanced synovial sarcoma, with a target action date set by the FDA for August 4, 2024, and is expected to be the first engineered T-cell therapy for solid tumors to receive commercial approval in the U.S. [2]. - The second product in the sarcoma franchise, lete-cel, is currently being investigated in the IGNYTE-ESO study [2][3]. Market Context - Year-to-date, Adaptimmune shares have risen by 46.3%, contrasting with a 7.9% decline in the industry, reflecting a strong performance despite recent challenges [2]. - Roche continues to collaborate with Poseida Therapeutics on allogeneic CAR-T therapies targeting hematological malignancies, indicating ongoing interest in cell therapy development within the industry [4].

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Jo Brewer - Chief Scientific Officer Conference Call Participants Graig Suvannavejh - Mizuho Securities Jonathan Chang - Leerink Partners Yanan Zhu - Wells Fargo Securities Operator Hello and welcome to Adaptimmune's Fourth Quarter an ...

Exhibit 99.1 Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed with FDA; will use data from Cohort 2 of pivotal SPEARHEAD-1 trial, which is fully enrolled Company is targeting launch of afami-cel upon receipt of FDA approval with commercial, manufacturing, and supply chain teams prepar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other juris ...

Adaptimmune Therapeutics (ADAP) is a clinical-stage biopharmaceutical company focused on developing novel T-cell therapies targeting cancer indications.The most advanced candidate in the company’s pipeline is afamitresgene autoleucel (or afami-cel), an engineered T-cell therapy for advanced synovial sarcoma, a malignant tumor that affects the tissue around the joints.Since the past month, shares of Adaptimmunehave soared 83.1% compared with the industry’s 7.0% rise. The upside can be attributed to the compl ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior Vice President-Late Stage Development Elliot Norry – Chief Medical Officer Jo Brewer – Chief Scientific Officer Gavin Wood – Chief Financial Officer Conference Call Participants Jerry Gong – Mizuho Securities Marc Frahm – TD Cowen Dylan Drakes – Leerink Partners Yanan Zhu – Wells Fargo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or ot ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2023 Results Conference Call August 9, 2023 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Conference Call Participants Tony Butler - EF Hutton Marc Frahm - TD Cowen Jonathan Chang - Leerink Partners Mara Goldstein - Mizuho Operator Good morning, ladies and gentlemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other j ...